150
Participants
Start Date
January 13, 2006
Primary Completion Date
December 15, 2015
Study Completion Date
December 15, 2015
Anagrelide
Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
Hydroxyurea
Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
University Multiprofile Hospital for active Treatment ''Alexandrovska'' Clinic of Haematology, Sofia
University of Debrecen Medical and Health Science Centre, Debrecen
Pandy Kalman Hospital of Bekes County, Gyula
University Multiprofile Hospital for Active Treatment ''Dr Georgi Stranski'' - Pleven, Pleven
Kaposi Mor Teaching Hospital, Kaposvár
University Multiprofile Hospital for Active Treament ''Sv. Marina'' - Varna Haematology Clinic, Varna
Petz Aladar County Teaching Hospital, Győr
Institute for Haematology of Clinical Centre of Serbia, Belgrade
CHU Angers Services des Maladies du Sang, Angers
Hopital Saint Louis - Centre d'Investigation Clinique, Paris
Uniwersyteckie Centrum Kliniczne Katedra i Klinika Hematologii i Transplantologii, Gdansk
Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin
Katedra i Klinika Onkologii i Chorob Wewnetrznych Akademii Medycznej, Warsaw
Klinika Hematologii Instytut Hematologii i Transfuzjologi, Warsaw
Hospitals da Universidade de Coimbra, Coimbra
Lead Sponsor
Shire
INDUSTRY